Cullinan Oncology

Deciphera Pharmaceuticals

BeiGene Ltd

Karyopharm Therapeutics

Blueprint Medicines

iTeos Therapeutics

MacroGenics Inc

Incyte Corporation

Exelixis Inc

Dilution score: 31/100 (MEDIUM), 23.7 months cash

13F fund flow: neutral, 21 institutional managers

Point72

ExodusPoint

Schonfeld

State Street

Two Sigma

Franklin Templeton

Millennium

BlackRock

Brevan Howard

REC-994 — spinocerebellar ataxia type 3

248 PubMed publications found for Cullinan Oncology

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer.

Short interest: 23.94% of float, squeeze risk: HIGH

SW convergence: 36/100 (Bearish Convergence), 0 bullish / 1 bearish signals

<article class="bts-verified-summary" data-ticker="CGEM">
<p>Cullinan Oncology (CGEM) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for CGEM were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001789972 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22CGEM%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0001789972

Cullinan Oncology (CGEM) — BioTechSigns Verified Summary

Cullinan Oncology (CGEM) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for CGEM were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001789972. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22CGEM%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11